Extended-Release Oral Minoxidil Shows Promise as First FDA-Approved Hair Loss Treatment for Women
核心洞察
Veradermics (搜索) is developing VDPHL01, an extended-release oral minoxidil formulation currently in Phase 3 trials for androgenetic alopecia (搜索) in both men and women.
Phase 2 data showed 21 male participants achieved an average increase of 37.5 hairs per square centimeter after two months and 47.3 hairs after four months.
The extended-release formulation aims to minimize cardiac risks associated with immediate-release oral minoxidil while optimizing hair growth benefits over 12-24 hours.
Veradermics (搜索), a Connecticut-based biopharmaceutical company, is advancing VDPHL01, an extended-release oral minoxidil formulation that could become the first FDA-approved oral treatment for female pattern hair loss (搜索). The drug is currently undergoing three Phase 3 studies, including the first-ever Phase 3 trial specifically for female pattern hair loss.
Addressing a Significant Unmet Medical Need
Pattern hair loss (搜索) affects approximately 80 million Americans, with 85 percent of men and 50 percent of women developing hair loss in their lifetime. Despite this prevalence, treatment options have remained extremely limited. Topical minoxidil (Rogaine) received FDA approval in 1991, while finasteride (Propecia) was approved as an oral treatment for males only in 1997. No oral treatment has ever been approved for female pattern hair loss (搜索).
"It's deeply personal, it's deeply psychological. It is essentially universal," explained Reid Waldman, CEO and dermatologist at Veradermics (搜索).
Extended-Release Technology Addresses Safety Concerns
VDPHL01 distinguishes itself from existing oral minoxidil through its extended-release formulation using proprietary hydrogel technology. Current oral minoxidil, originally developed as a blood pressure medication, delivers a brief spike to the bloodstream lasting only a couple of hours, which can pose cardiovascular risks including pericardial effusion (搜索).
"It comes into the body very quickly, which is really great if you want to rapidly control someone's blood pressure. It's not so great for driving hair growth with reduced cardiac risk," Waldman explained. The majority of immediate-release oral minoxidil is eliminated from the body within two hours and falls below a critical hair threshold within four hours.
The extended-release formulation aims to provide consistent exposure at the hair follicle (搜索) over 12 to 24 hours while minimizing cardiac risks. "We want to give consistent exposures at the hair follicle to the minoxidil with a slow release," Waldman noted.
Promising Phase 2 Results
Phase 2 data demonstrated encouraging efficacy outcomes. In one study, 21 male participants showed an average increase of 37.5 hairs per square centimeter in the target area after two months, rising to 47.3 hairs after four months. Over 90 percent of participants experienced a double-digit increase in hair count, an objective metric.
Nearly 91 percent of participants reported visible improvement, and 95 percent expressed greater satisfaction with their hair coverage. Notably, visible regrowth was observed at two months, significantly faster than the typical six-month timeline expected in clinical practice.
"At month two, we saw a visibly noticeable regrowth," Waldman said. "So it was very encouraging to us to see hair growth so quickly."
Safety Profile and Diverse Population
The Phase 2 study reported no serious treatment-related cardiac adverse events, addressing a key concern with immediate-release oral minoxidil. The trials include participants with diverse hair and skin types, with "strong representation across different hair patterns, hair textures, and ethnic groups," according to Waldman.
The treatment also avoids the hormonal side effects associated with finasteride, which is only approved for male use.
Regulatory Timeline and Clinical Significance
Veradermics (搜索) anticipates having initial Phase 3 male data in the first half of 2026, with complete male data available throughout 2026. The company plans to file for FDA approval if trial results remain positive.
Dr. Jerry Shapiro, Professor of Dermatology at New York University School of Medicine and Veradermics (搜索) advisor, stated, "As a clinician and researcher, I have not seen an investigational therapy for hair loss indicate the potential for quick results like VDPHL01 based on two- and four-month data. I believe VDPHL01 could become the new benchmark for treating pattern hair loss (搜索) in both women and men."
If approved, VDPHL01 would represent the first new prescription hair-growth therapy in nearly 30 years and the first oral treatment specifically approved for female pattern hair loss (搜索), potentially addressing a significant unmet medical need for millions of patients.